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Purpose or Objective: To determine the optimum 
combination of treatment parameters between pitch, field 
width (FW) and number of irradiation fields for left-sided 
whole breast irradiation using static tomotherapy (« 
TomoDirect™ »). 
 
Material and Methods: 15 patients already treated with 
conformal radiotherapy for left-sided breast cancer without 
lymph nodes were selected for this study. A total of 180 
TomoDirect™ plans were created by varying the field width 
(2.5 and 5 cm), the pitch (0.125, 0.250 and 0.5 
cm/projection) and the number of irradiation fields (2 and 
4). Modulation factor (MF) was set to 2 and dynamic jaws 
were not available. Prescribed dose was 50 Gy in 25 fractions 
without tumoral boost. Constraints were applied on the 
planning treatment volume (PTV) to ensure that 98% of the 
PTV receives at least 95% of the prescribed dose and 2% 
receives at most 107%. Treatment plans were assessed 
collecting Homogeneity Index (HI) for the PTV, mean doses 
(heart, ipsilateral and contralateral lung) and maximum dose 
(contralateral breast) for the organs-at-risk (OAR), integral 
dose to the patient and beam-on time. To assess whether 
breast size has an impact on dose homogeneity to the PTV, 
we separated the 15 patients into 2 cohorts of small (volume 
< 600 cc) and large (> 600 cc) PTV and compared HI. 
 
Results: Modifying the pitch has no effect on either plan 
quality (PTV and OAR) or on irradiation time. Increasing the 
number of beams from 2 to 4 has no significant effect on OAR 
doses, but improves the HI of the PTV (0.068 ± 0.010 for 2 
fields and 0.061 ± 0.011 for 4 fields) without altering 
significantly irradiation time (4.48 ± 1.27 min for 2 fields and 
4.82 ± 1.30 min for 4 fields). Comparison of HI between small 
and large PTV shows that PTV volume has no significant 
effect on HI. Also, HI improvement does not depend on PTV 
volume, meaning that switching from 2 to 4 fields of 
irradiation is always beneficial (~ 10% better). Beam-on times 
are lowered using a FW = 5 cm (3.49 ± 0.37 min) rather than 
a FW = 2.5 cm (5.81 ± 0.70 min). On the other hand, the FW 
has no significant impact on OAR or PTV doses, except for the 
integral dose that is respectively 95.72 ± 35.22 Gy.L for a FW 
= 2.5 cm and 105.3 ± 38.1 Gy.L for a FW = 5 cm. Keep in mind 
that these results are obtained with a fixed MF = 2. 
 
Conclusion: While setting the modulation factor to 2, pitch 
value seems to have no impact on planning quality or on 
irradiation time. A field width of 5 cm with 4 fields of 
irradiation is a good combination of treatment parameters for 
treating left-sided whole breast cancer with TomoDirect™ if 
dynamic jaws are available. If not the case, a field width of 
2.5 cm is more suitable so that the integral dose to patients 
is lowered and radiation-induced secondary malignancies are 
minimized. This study will be completed by delivery QA to 
confirm that delivered doses match calculated ones. 
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Purpose or Objective: From the biological aspects of 
prostate cancer, hypofractionated external beam radiation 
therapy (EBRT) or high-dose-rate brachytherapy (HDR-BT) has 
been considered as a treatment choice for prostate cancer to 
improve local control, especially for high risk disease because 
the alpha-beta ratio for prostate cancer was around 1.5-3 Gy, 
lower than that for other cancers. Therefore, the purpose of 
this study is to evaluate outcomes and toxicities of 
hypofractionated EBRT combined with HDR-BT for high risk 
prostate cancer. 
 
Material and Methods: We retrospectively analyzed 111 
patients with localized prostate cancer (T1-3N0M0) that was 
defined as high risk disease based on the D’Amico 
classification, which includes cases of stage T2c to T3b or 
those with Gleason score of 8 to 10 or prostate-specific 
antigen (PSA) greater than 20 ng/mL. All patients had 
received hypofractionated EBRT (45 Gy in 15 fractions every 
other weekday for 5 weeks) followed by HDR-BT (18 Gy in 2 
fractions for one day) between June 1, 2007 and September 
30, 2011 at our institution. Androgen deprivation therapy 
(ADT) consisted of 3 to 6 months’ neoadjuvant ADT before 
and during radiation therapy and 6 months’ adjuvant ADT 
after radiation therapy. Biochemical failure was defined as 
PSA nadir plus 2.0 ng/mL according to the Phoenix definition. 
We scored genitourinary (GU) and gastrointestinal (GI) 
toxicities based on the Common Terminology Criteria for 
Adverse Events Version 4, and calculated the rates of overall 
and biochemical-free survival using the Kaplan-Meier method, 
timed from the completion of the HDR-BT to death or earliest 
failure. Statistical analyses were performed by using SPSS 
software. 
 
Results: During follow-up (median, 62 months; range, 4 to 99 
months), 24 of 111 patients (21.6%) experienced biochemical 
failure (median, 41.5 months; range, 12.7 to 72.1 months). 
The rates of 5-year overall survival and biochemical-free 
survival were 99.0% and 80.3%, respectively. At the time of 
analysis, only 1 patient had died of other disease. Among 24 
patients with biochemical failure, 1 pateint developed bone 
metastasis, 2 patients developed pelvic lymph node 
recurrence, and 21 patients diagnosed with PSA failure alone. 
GU acute toxicity was Grade 1 or less in 99 patients and 
Grade 2 in 12 patients. GU late toxicity was Grade 1 or less in 
108 patients and Grade 2 in 3 patients. GI toxicity including 
rectal bleeding was Grade 1 or less in 109 patients and Grade 
2 in 2 patients. 
 
Conclusion: The results of this study suggest that 
hypofractionated EBRT combined with HDR-BT can be 
feasible for high risk prostate cancer, although follow-up 
period is not long enough to get a definitive conclusion. 
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Purpose or Objective: With improvements in survival for 
good performance status patients with glioblastoma, some 
patients will survive to develop significant neurocognitive 
dysfunction. This retrospective planning study quantifies 
hippocampal radiation doses in twenty-five patients with 
glioblastoma receiving radical chemo-radiation therapy, and 
evaluates the potential for dose reduction using helical IMRT 
(Tomotherapy).  
 
